# Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT05683249** · PHASE2,PHASE3 · COMPLETED · sponsor: **Neurocentria, Inc.** · enrollment: 223 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** NRCT-101-SR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05683249
- **Lead sponsor:** Neurocentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-25
- **Primary completion:** 2024-01-17
- **Final completion:** 2024-01-17
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683249, "Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05683249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*